Sign inJoin waitlistJoin the waitlist

Jeffrey Clarke

Associate Professor of Medicine · Duke University Hospital

Credentials: · · ·

History

Duke Cancer Institute
2018–Present
Duke University Hospital
Present

Duke University Hospital
2011–2015
Internal Medicine
Duke University Hospital
Chief Resident2012–2013
2008–2011
Indiana University School of Medicine
2004–2008

Research

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update
Systematic review or meta-analysis · Journal of Clinical Oncology · 2013 · 616 citations
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014
Journal of Clinical Oncology · 2015 · 571 citations
Leptomeningeal disease: current diagnostic and therapeutic strategies
Review · Oncotarget · 2017 · 178 citations

Neal Ready
14 papers
Jeffrey Crawford
11 papers
Scott Antonia
11 papers
Thomas Stinchcombe
11 papers
Jonathan Goldman
7 papers
Lin Gu
7 papers · 7 as a resident
MJ
Melissa Johnson
7 papers
HH
Herbert Hurwitz
6 papers
Kamran Mahmood
6 papers
Suresh Ramalingam
6 papers
Anne Tsao
5 papers
April Salama
5 papers

Grants

Race-Related Differential RNA Splicing: Novel Targets for Precision Oncology in Non-Small Cell Lung Cancer
National Cancer Institute · R01
PI · $377.1K · Duke University
2020–2021

Clinical trials

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer
Principal investigator · Withdrawn · Phase 2
Duke University
2023–2026
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Principal investigator · Terminated · Phase 2
Jeffrey Clarke
2023–2025
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Principal investigator · Terminated · Phase 2
Jeffrey Clarke
2021–2022
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
Principal investigator · Completed · Phase 1
Edward Patz
2020–2024